Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease
Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease
复制标题
DOI：
10.1016/j.neulet.2007.08.010
复制
发表时间：
2007-09-20
影响因子：
2.5
通讯作者：
Hashimoto, Makoto
中科院分区：
文献类型：
--
作者：
Waragai, Masaaki;Nakai, Masaaki;Hashimoto, Makoto
DJ-1是一种多功能蛋白，其基因突变导致的功能丧失可能是家族性帕金森病(PD)的致病因素。最近的一项研究表明，在包括散发性帕金森病、阿尔茨海默病(AD)和中风在内的各种神经系统疾病中，DJ-1分子在脑和脑脊液中表达上调，这增加了DJ-1可能成为这些疾病的潜在生物标志物的可能性。在此背景下，本研究的主要目的是确定DJ-1是否在PD患者的血浆中增加。采用免疫印迹和酶联免疫吸附试验对散发性帕金森病患者、路易体痴呆患者和健康对照组的血浆标本进行分析。结果显示，PD组(n=104)血浆DJ-1水平明显高于对照组(n=80)(P<0.05)。PD晚期(n=52，YahrⅢ-IV)血浆DJ-1水平高于PD早期(n=52，Yahr I-II)(p<；0.05)，提示血浆DJ-I水平与PD病情严重程度相关。DLB组(n=30)血浆DJ-1水平也显著高于对照组和PD早期(p<；0.01)。综上所述，这些结果提示，血浆DJ-1可能是一种有用的生物标志物，可用于评估帕金森病的病情严重程度，并可能在其他路易体疾病。(C)2007爱思唯尔爱尔兰有限公司。保留所有权利。
DJ-1 is a multifunctional protein whose loss of function by gene mutations may play a causative role for familial Parkinson's disease (PD). A recent study has shown that the expression of this molecule is upregulated in both brains and cerebrospinal fluids (CSF) in various neurological disorders, including sporadic PD, Alzheimer's disease (AD) and stroke, raising a possibility that DJ-1 could be a potential biomarker for these diseases. In this context, the main objective of the present study was to determine if DJ-1 was increased in the plasma of PD patients. For this purpose, blood plasma samples collected from sporadic PD patients, dementia with Lewy bodies (DLB) and healthy age-matched controls were analyzed by immunoblotting and enzyme-linked immunosorbent assay. The results showed that the plasma DJ-1 levels in PD (n = 104) were higher than those in control (n = 80) (p < 0.05). Moreover, the plasma DJ-1 levels in the advanced stage of PD (n = 52, Yahr III-IV) were higher than those in the early stage of PD (n = 52, Yahr I-II) (p < 0.05), demonstrating that the plasma DJ- I was correlated with the disease severity in PD. Plasma DJ-1 levels were also significantly higher in DLB (n = 30) compared with both controls and early stage of PD (p < 0.01). Taken together, these results suggest that the plasma DJ-1 could be a useful biomarker for the evaluation of the disease severity in PD and possibly in other Lewy body diseases. (c) 2007 Elsevier Ireland Ltd. All rights reserved.